Changyao Group(300391)

Search documents
*ST长药(300391) - 关于长江医药控股股份有限公司2025年第二次临时股东大会的法律意见书
2025-05-23 11:00
关于长江医药控股股份有限公司 2025 年第二次临时股东大会的 湖北英达律师事务所 法律意见书 中国武汉市新华路 186 号福星国际商会大厦 18 楼 电话:86.27.85350032 传真:86.27.85350997 邮政编码:430022 网址:www.yingdalaw.com 二〇二五年五月 英达律师事务所 法律意见书 湖北英达律师事务所 关于长江医药控股股份有限公司 2025 年第二次临时股东大会的 法律意见书 致:长江医药控股股份有限公司 湖北英达律师事务所(下称"本所")接受长江医药控股股份有限公司(下称 "公司")委托,指派本所律师宋浩、周凌雷现场见证公司于 2025 年 5 月 23 日召 开的 2025 年第二次临时股东大会(以下简称"本次股东大会"),并根据《中华 人民共和国公司法》(下称"《公司法》")、《中华人民共和国证券法》(下称 "《证券法》")、中国证券监督管理委员会发布的《上市公司股东大会规则》(下 称"《股东大会规则》")等相关法律、法规、规范性文件以及《长江医药控股股 份有限公司章程》(下称"《公司章程》")的有关规定,就本次股东大会的召集 和召开程序、出席会议人员的 ...
格隆汇公告精选︱比亚迪8月新能源汽车销量17.5万辆;丽珠集团新冠疫苗被纳入序贯加强免疫紧急使用
Ge Long Hui· 2025-05-19 01:20
Group 1 - BYD reported August sales of 174,915 new energy vehicles, a year-on-year increase of 184.84% [1] - Cumulative sales from January to August reached 978,795 units, representing a year-on-year growth of 267.31% [1] - The company sold 5,092 new energy passenger vehicles overseas in August [1] Group 2 - Zhongke Electric's subsidiary plans to establish a joint venture with Chongqing Fudi for the production of anode materials, with a registered capital of 1 billion RMB [2] - Zhongke Electric's subsidiary will contribute 650 million RMB, while Chongqing Fudi will contribute 350 million RMB [2] Group 3 - Yuyuan Group intends to transfer 13% of its shares in Jinhuijiu for approximately 1.937 billion RMB, reducing its stake to 25% [3] - The company plans to further reduce its holdings by more than 5% within the next six months [3] Group 4 - Lizhu Group's recombinant COVID-19 fusion protein vaccine has been included in the emergency use for sequential booster immunization [4] Group 5 - Guanghui Energy plans to repurchase shares worth between 800 million and 1 billion RMB to support employee stock ownership plans [5] Group 6 - Cambrian has launched four cloud-based intelligent chips, although mass sales will require a longer time frame and initial technical service investments [7] Group 7 - LePu Medical has received approval from the China Securities Regulatory Commission for the issuance of Global Depositary Receipts (GDRs) and listing on the Swiss Stock Exchange [9] - The GDR issuance will correspond to no more than 180,458,875 new A-shares [9] Group 8 - Fushi Holdings' subsidiary has entered into an exclusive advertising agency cooperation with the Central Radio and Television Station's automotive channel for three years [10] Group 9 - Guangzhou Port's container throughput in August was 1.981 million TEUs, a year-on-year increase of 2.4% [11] - The total cargo throughput for August was 44.788 million tons, a decrease of 0.6% [11] Group 10 - Ningbo Port expects to complete a container throughput of 3.58 million TEUs in August, a year-on-year increase of 10.2% [12] - The total cargo throughput is projected to decline by 3.0% [12] Group 11 - Ming Tai Aluminum reported a 7% year-on-year decrease in aluminum plate and strip sales in August, while aluminum profile sales increased by 47% [13] Group 12 - Electric Power Investment plans to invest in multiple wind and solar projects, with total static investments of 1.585 billion RMB for wind and 538 million RMB for solar [14] Group 13 - Northeast Pharmaceutical has signed a cooperation agreement with MedAbome for the development of the MAb11-22.1 antibody project [19] Group 14 - New Five Feng plans to acquire equity in Tianxin Seed Industry and several other companies for a total price of approximately 2.208 billion RMB [26] Group 15 - Sumeida's subsidiary plans to transfer 100% equity of eight photovoltaic power station project companies, with an estimated transaction value of 657 million RMB [27] Group 16 - *ST Tongzhou intends to acquire 51% equity in Tongtaiwei, fulfilling the capital contribution obligation of 10.2 million RMB [29] Group 17 - Tianyin Holdings' subsidiary plans to invest 120 million RMB in Xundong Xintong to acquire 40% equity [30] Group 18 - Hainan Haiyao plans to publicly transfer 43% equity in Shanghai Lishengte to attract new investors [31] Group 19 - New Asia Process plans to transfer 7.76% of its shares to Xiangcai New Materials at a price of 5.274 RMB per share [32] Group 20 - Lanwei Medical plans to raise no more than 664 million RMB through a private placement for provincial laboratory construction projects [34] Group 21 - Lida New Materials plans to issue convertible bonds to raise no more than 300 million RMB for a new aluminum material project [35] Group 22 - Gekewei has successfully launched its 12-inch CIS integrated circuit project, achieving over 95% yield [51] Group 23 - Baijin Medical's tricuspid valve ring product has received registration approval [52] Group 24 - Shanghai Pharmaceuticals has received approval to initiate Phase I clinical trials for a recombinant anti-CD20 humanized monoclonal antibody [53] Group 25 - Junda Co. has increased the production capacity of its solar cell production base project from 8GW to 10GW [54]
*ST长药(300391) - 重大诉讼的进展公告
2025-05-14 13:02
2025年5月12日,长江医药控股股份有限公司(以下简称"公司"、"长药 控股")收到湖北省武汉市中级人民法院执行裁定书。湖北省武汉市中级人民法 院所在地为湖北省武汉市江汉区常青路156号。诉讼各方当事人如下: 申请执行人:武汉农村商业银行股份有限公司武昌支行,负责人万国庆。 被执行人:湖北长江星医药股份有限公司,法定代表人罗飞;湖北长江丰医 药有限公司,法定代表人贺元峰;湖北长江源制药有限公司,法定代表人罗飞; 石首市国际大酒店有限公司,法定代表人张芳芳;湖北长江大药房连锁有限公司, 法定代表人阳勇;湖北舒惠涛药业有限公司,法定代表人胡士会;湖北长江大药 房连锁武汉有限公司,法定代表人张兰;长江医药控股股份有限公司,法定代表 人胡士会;罗明、张莉、田良辉。 二、有关案件的基本情况 原告武汉农村商业银行股份有限公司武昌支行与被告湖北长江星医药股份 有限公司、湖北长江丰医药有限公司、湖北长江源制药有限公司、石首市国际大 酒店有限公司、湖北长江大药房连锁有限公司、湖北舒惠涛药业有限公司、湖北 长江大药房连锁武汉有限公司、长江医药控股股份有限公司、罗明、张莉、田良 辉金融借款合同纠纷案的基本情况,详见公司于2023 ...
*ST长药(300391) - 2024年度股东会决议公告
2025-05-13 11:45
证券代码:300391 证券简称:*ST长药 编号:2025-057 长江医药控股股份有限公司 2024年度股东会决议公告 1、本次股东会无增加、变更、否决提案的情况; 本公司及董事会全体成员保证信息披露内容真实、准确和完整,不存在虚假记载、误 导性陈述或者重大遗漏。 特别提示: 2、本次股东会以现场投票表决和网络投票表决的方式召开。 一、会议召开和出席情况 1、召集人:公司董事会 2、召开方式:现场投票与网络投票相结合的方式 3、召开时间: (1)现场会议时间:2025 年 5 月 13 日(星期二)下午 15:30 6、会议主持人:公司董事长王波先生。 7、会议出席情况: (1)出席会议的总体情况 参加会议的股东(代理人)共 91 名,所持(代理)股份 38,821,200 股,占 1 (2)网络投票时间:2025 年 5 月 13 日。其中,通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 5 月 13 日上午 9:15-9:25,9:30-11:30, 下午 13:00-15:00;通过深圳证券交易所互联网系统投票的具体时间为 2025 年 5 月 13 日 9:15-15:00。 4、 ...
*ST长药(300391) - 湖北英达律师事务所关于长江医药控股股份有限公司2024年年度股东大会的法律意见书
2025-05-13 11:45
湖北英达律师事务所 关于长江医药控股股份有限公司 2024 年年度股东大会的 法律意见书 中国武汉市新华路 186 号福星国际商会大厦 18 楼 电话:86.27.85350032 传真:86.27.85350997 邮政编码:430022 网址:www.yingdalaw.com 二○二五年五月 英达律师事务所 法律意见书 湖北英达律师事务所 关于长江医药控股股份有限公司 2024 年年度股东大会的 法律意见书 致:长江医药控股股份有限公司 湖北英达律师事务所(下称"本所")接受长江医药控股股份有限公司(下称 "公司")委托,指派本所律师宋浩、周凌雷现场见证公司于 2025 年 5 月 13 日 召开的 2024 年年度股东大会(以下简称"本次股东大会"),并根据《中华人民 共和国公司法》(下称"《公司法》")、《中华人民共和国证券法》(下称"《证 券法》")、中国证券监督管理委员会发布的《上市公司股东大会规则》(下称 "《股东大会规则》")等相关法律、法规、规范性文件以及《长江医药控股股份 有限公司章程》(下称"《公司章程》")的有关规定,就本次股东大会的召集和 召开程序、出席会议人员的资格和召集人资格、 ...
新股发行及今日交易提示-20250512





HWABAO SECURITIES· 2025-05-12 09:05
Group 1: New Stock Offerings - ST Xinchao (600777) has a tender offer period from April 23, 2025, to May 22, 2025[1] - Puli Tui (300630) has 7 trading days remaining until the last trading day[1] - ST Zhongcheng (300208) reported severe abnormal fluctuations[1] Group 2: Trading Alerts - Jintai (300225) and other stocks are under observation for trading alerts due to abnormal fluctuations[1] - ST Yida (600608) and ST Huke (600608) are also flagged for trading alerts[1] - Multiple stocks including ST Shengda (002259) and ST Yushun (002289) are under scrutiny for trading activities[1] Group 3: Recent Announcements - Guofang Group (601086) and other companies have made recent announcements regarding their stock activities[1] - A total of 7 trading days remain for several stocks approaching their last trading day[1] - Various companies including ST Huada (603580) and ST Aiai (603580) have made recent disclosures[1]
*ST长药(300391) - 300391*ST长药投资者关系管理信息20250509
2025-05-09 10:48
Group 1: Company Restructuring and Financial Status - The company signed a restructuring investment agreement on May 6, 2025, and the pre-restructuring work is progressing in an orderly manner [1] - The audited net assets attributable to the parent company for 2024 are negative, posing a risk of stock delisting [2] - If the restructuring is successful, it will significantly improve the company's financial status and reduce debt [3] Group 2: Stock Increase and Capital Structure - The company plans to increase its capital by converting 10 shares into 15 shares, resulting in a total share capital increase from 350,336,112 shares to 875,840,280 shares [2] - The conversion price is set at 2.42 CNY per share, with a total of 525,504,168 shares available for conversion [2] - Remaining shares after the restructuring will be used to repay ordinary creditors at a price not lower than 10 CNY per share [2] Group 3: Investor Relations and Market Concerns - The company is addressing investor concerns regarding stock price fluctuations influenced by various factors, including company performance and market conditions [2] - There is no current request from industry investors to change the company's main business [2] - The company has not received any consent letters from the China Securities Regulatory Commission regarding the restructuring [3] Group 4: Management and Operational Changes - If the restructuring is successful, the controlling shareholder will change to Sichuan Jiadaobowen Ecological Technology Co., Ltd. [3] - The new industry investors are expected to recommend talent to enhance the company's operational capabilities [4] - The company currently has no specific plans for its photovoltaic sector [3]
【盘中播报】24只个股跨越牛熊分界线
Zheng Quan Shi Bao Wang· 2025-05-09 04:16
Core Points - The Shanghai Composite Index is at 3343.28 points, slightly down by 0.26%, with a total trading volume of 590.62 billion yuan [1] - 24 A-shares have surpassed their annual moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Huaihe Energy (600575) has the highest deviation rate at 9.45%, with a daily increase of 10.03% and a turnover rate of 4.61% [2] - *ST Changyao (300391) follows with a deviation rate of 3.71%, increasing by 4.37% today [2] - Shuiyang Co., Ltd. (300740) shows a deviation rate of 3.58% with an 8.70% increase [2] Other Notable Stocks - *ST Chuangxing (600193) has a deviation rate of 3.47% and a daily increase of 4.94% [2] - Yahua Electronics (301337) has a deviation rate of 3.40% with a 5.06% increase [2] - Shaanxi Huada (301517) shows a 4.25% increase and a deviation rate of 3.38% [2] Market Overview - The overall A-share market is experiencing fluctuations, with a total trading volume of 590.62 billion yuan, indicating active trading [1]
*ST长药意向重整投资方浮出水面 海康威视第二大股东、630亿元身家投资大佬拟入主
Mei Ri Jing Ji Xin Wen· 2025-05-08 13:45
Core Viewpoint - *ST Changyao has made significant progress in its restructuring process, with the main investor, Jia Dao Bowan, set to become the controlling shareholder after a capital increase and share transfer agreement [1][2][6]. Company Summary - *ST Changyao primarily engages in the production and sale of traditional Chinese medicine pieces, as well as the wholesale of pharmaceuticals, health products, and medical devices [2]. - The company initiated pre-restructuring in January, and after over three months, it signed restructuring investment agreements with six investors, including Jia Dao Bowan and other financial investors [2][6]. - The restructuring plan involves a capital increase of approximately 526 million shares, with Jia Dao Bowan investing 593 million yuan to acquire 245 million shares at a price of 2.42 yuan per share [2][6]. Financial Performance - In 2024, *ST Changyao reported a net profit loss of 628 million yuan, with revenue plummeting from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [6]. - The company faces significant financial distress, including overdue debts and lawsuits from creditors, leading to frozen bank accounts and asset seizures [6]. Investor Background - Jia Dao Bowan, controlled by Gong Hongjia and Chen Chunmei, is the second-largest shareholder of Hikvision and has a strong background in investment, particularly in the security sector [1][5]. - Gong Hongjia has committed to providing up to 1 billion yuan to support *ST Changyao's restructuring and operational needs [5]. Strategic Implications - The acquisition of controlling interest in *ST Changyao marks a shift in Jia Dao Bowan's investment strategy from purely financial investments to seeking operational control [7]. - The investment aligns with Jia Dao Bowan's existing business in ecological agriculture, which may synergize with *ST Changyao's traditional medicine operations [7]. Industry Context - The restructuring of *ST Changyao is part of a broader trend in the pharmaceutical industry, where companies are seeking to revitalize through mergers and acquisitions amid changing market dynamics [8]. - Other companies in Hubei, such as Renfu Pharmaceutical and *ST Meigu, are also undergoing restructuring, indicating a potential shift in investment focus towards revitalizing distressed assets in the healthcare sector [8].
600亿资本大佬出手!拟入主这只ST股
Zheng Quan Shi Bao Wang· 2025-05-08 12:03
Core Viewpoint - A company involved in "gutter oil" processing has emerged as an investor in the restructuring of *ST Changyao, indicating a significant shift in the company's ownership and potential future direction [1][4]. Investment and Financial Structure - *ST Changyao has signed restructuring investment agreements with two industrial investors, Sichuan Jiadaobowen Ecological Technology Co., Ltd. and Haowei Biological, with plans to increase its total share capital from 350 million shares to 876 million shares through a capital reserve transfer [3][4]. - Jiadaobowen will pay 593 million yuan to acquire 245 million shares of *ST Changyao, becoming the controlling shareholder post-restructuring [4]. Background of Investors - Jiadaobowen is backed by prominent capital figures Gong Hongjia and Chen Chunmei, who control 97.95% of the company [5][6]. - Jiadaobowen's total assets are reported at 1.22 billion yuan, with a net asset of 650 million yuan, and it recorded a revenue of 176 million yuan with a net loss of 16.09 million yuan in 2024 [5]. Historical Context and Market Activity - Gong Hongjia has a notable history in the capital market, having founded several successful companies and achieved significant investment returns, including a 20,000-fold return from an investment in Hikvision [7][10]. - The couple has been active in the A-share market, previously investing in companies like Tianxiang Environment and *ST Kaiyuan, demonstrating a pattern of engaging in restructuring opportunities [11][14]. Current Challenges - *ST Changyao is currently facing difficulties, with its 2024 financial report receiving a non-standard opinion from auditors, indicating a heavy burden for the company to maintain its listing status in 2025 [12].